. Author manuscript; available in PMC: 2015 Jun 15.

Published in final edited form as: J Control Release. 2005 Dec 2;110(3):587–594. doi: 10.1016/j.jconrel.2005.10.029

Table 2.

Pharmacological availability of various ILPs administered orally to Wistar rats

Dose	Preparation	AAC			PA

(IU/kg)		(% glu. reduc. · h)			(%)
10	Insulin solution	^*	0.7 ± 0.6	^**	^*	0	^**
	L-ILP		19.0 ± 16.6			3.3 ± 2.9
	SS-ILP		54.6 ± 11.6			9.5 ± 2.0
25	Insulin solution	^*	1.3 ± 0.8	^**	^*	0	^**
	L-ILP		4.7 ± 3.2			0.3 ± 0.2
	SS-ILP		106.1 ± 47.3			7.4 ± 3.3
50	Insulin solution	^*	1.7 ± 1.2	^**	^*	0	^**
	L-ILP		14.3 ± 9.9			0.5 ± 0.3
	SS-ILP		51.5 ± 10.3			1.8 ± 0.3

AAC denotes area above the curve.

PA denotes relative pharmacological availability.

Each value represents mean ± S.E.

Statistically significant difference between the preparation: p <0.01, **;

p <0.05, *.